FDA Grants Multiple Approvals to Takeda for Rare Blood Disorders and Cancer Treatments
The FDA has approved Adzynma, the first recombinant protein product for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. cTTP is caused by a mutation in the ADAMTS13 gene, resulting in a deficiency of the ADAMTS13 enzyme responsible for regulating blood clotting. Adzynma is a purified recombinant form of the enzyme that can be administered prophylactically or on-demand to reduce the risk of clotting/bleeding and treat acute events. The safety and effectiveness of Adzynma were demonstrated in a global study, and the most common side effects include headache, diarrhea, and abdominal pain. The approval of Adzynma provides a much-needed treatment option for patients with cTTP.
- FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder FDA.gov
- FDA signs off on Takeda's colorectal cancer drug Fruzaqla FiercePharma
- Takeda Pharma gets US FDA approval for rare blood disorder therapy Reuters
- Dr Marshall on the FDA Approval of Fruquintinib in mCRC OncLive
- Takeda scores second FDA approval this week with green light for rare blood clotting disorder drug Adzynma FiercePharma
- View Full Coverage on Google News
Reading Insights
0
0
3 min
vs 4 min read
82%
620 → 112 words
Want the full story? Read the original article
Read on FDA.gov